María Ángeles Puche Larrubia

Dr. María Ángeles Puche Larrubia

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
SCSANDRA ALCARAZ CLARIANA
SANDRA ALCARAZ CLARIANA
LGLOURDES GARCIA-LUQUE
LOURDES GARCIA-LUQUE
JGJuan Luis Garrido-Castro
Juan Luis Garrido-Castro
IAI. Concepción Aranda-Valera
I. Concepción Aranda-Valera
MLMaría Lourdes Ladehesa-Pineda
María Lourdes Ladehesa-Pineda
Francisco Alburquerque-SendínFrancisco Alburquerque-Sendín
Francisco Alburquerque-Sendín
Different musculoskeletal disorders are a source of pain in the spinal region; most of them can be divided into mechanical, such as low back pain (LBP), or inflammatory origins, as is the case of axial spondyloarthritis (axSpA). Nevertheless, insufficient information is available about the muscle negative consequences of these conditions. Thus, the objective of this study was to identify whether mechanical muscle properties (MMPs) of cervical and lumbar muscles are different between patients with axSpA, subacute LBP (sLBP), and healthy controls. Furthermore, we aimed identify whether MMPs were related to sociodemographic and clinical variables in various study groups. The MMPs, sociodemographic, and clinical variables were obtained in 43 patients with axSpA, 43 subjects with sLBP, and 43 healthy controls. One-way ANOVAs and ROC curves were applied to identify whether the MMPs could differentiate between the study groups. Intra-group Pearson r coefficients to test the associations between MMPs and the rest of the variables were calculated. The results showed that axSpA subjects have a higher tone and stiffness and a lower relaxation and creep than sLBP and healthy ones (p < 0.05). All lumbar and cervical MMPs, except for decrement, could correctly classify axSpA and healthy subjects and axSpA and sLBP patients (in both cases, Area Under the Curve > 0.8). However, no MMP could differentiate between sLBP and healthy subjects. Each group had a different pattern of bivariate correlations between MMPs and sociodemographic and clinical data, with a worse state and progression of the axSpA group associated with a higher tone and stiffness in both spinal regions. This study supports that MMPs are different and show different patterns of correlations depending on the type of spinal pain.

17 March 2023 in Joint Bone Spine
Verified
Journal Article
Closed access
MLMaría Ángeles Puche Larrubia
María Ángeles Puche Larrubia
LLLourdes Ladehesa-Pineda
Lourdes Ladehesa-Pineda
MLMaría Dolores López-Montilla
María Dolores López-Montilla
NBNuria Barbarroja
Nuria Barbarroja
AEAlejandro Escudero-Contreras
Alejandro Escudero-Contreras
CLClementina López-Medina
Clementina López-Medina

21 September 2023 in RMD Open
Verified
Journal Article
Open access
PDF file
MLMaría Ángeles Puche Larrubia
María Ángeles Puche Larrubia
LLLourdes Ladehesa-Pineda
Lourdes Ladehesa-Pineda
JVJanitzia Vázquez-Mellado
Janitzia Vázquez-Mellado
AEAlejandro Escudero-Contreras
Alejandro Escudero-Contreras
JGJordi Gratacós
Jordi Gratacós
Clementina López-MedinaClementina López-Medina
Clementina López-Medina
Objective To describe and analyse the initial symptoms attributable to patients with spondyloarthritis (SpA) and their association with HLA-B27 status. Methods This was an observational, cross-sectional and multicentre study with patients who fulfilled the European Spondyloarthropathy Study Group criteria for SpA from the Registry of Spondyloarthritis of Spanish Rheumatology (REGISPONSER) and Ibero-American Registry of Spondyloarthropathies (RESPONDIA) united registries. Differences in the first sign(s) or symptom(s) were compared across diagnoses and between HLA-B27 status. The diagnostic delay between patients who start the disease with musculoskeletal manifestations (MMs) and extra-MMs (EMMs) was compared. Results A total of 4067 patients were included (2208 from REGISPONSER and 1859 from RESPONDIA) (ankylosing spondylitis (AS): 68.3%, psoriatic arthritis (PsA): 19.9%, undifferentiated SpA: 11.8%). Overall, 3624 (89.1%) patients initiated the disease with MMs and 443 (10.9%) with EMMs. Low back pain (61.7%) and lower-limb arthritis (38.5%) were the most frequent initial symptoms. In AS patients, the absence of HLA-B27 seems to be related to an increase in the probability of starting the disease with cervical pain and peripheral manifestations. In PsA, the onset of arthritis and psoriasis was more prevalent in HLA-B27-negative patients, while initiation with axial manifestations was more predominant in HLA-B27-positive patients. The diagnostic delay was longer in patients with initial MMs than in those with EMMs (7.2 (34.8) vs 4.5 (7.6) years, respectively). Conclusion In this SpA population, MMs were the most prevalent initial symptoms, with differences across diagnoses and depending on the presence of the HLA-B27 antigen.

1 January 2021 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
PDF file
MLMaría Ángeles Puche Larrubia
María Ángeles Puche Larrubia
MLMaría Lourdes Ladehesa-Pineda
María Lourdes Ladehesa-Pineda
PFPilar Font-Ugalde
Pilar Font-Ugalde
AEAlejandro Escudero-Contreras
Alejandro Escudero-Contreras
AMAnna Moltó
Anna Moltó
ECEduardo Collantes-Estévez
Eduardo Collantes-Estévez
Introduction: The aim of the study was to compare the prevalence of comorbidities between patients with axial and peripheral phenotypes and to evaluate the role of psoriasis in such comorbidities. Methods: Patients from the cross-sectional Assessment in SpondyloArthritis Inter-national Society (ASAS)-COMOSPA study were classified as having either the axial (presence of sacroiliitis on X-ray or MRI) or peripheral phenotype (absence of sacroiliitis AND presence of peripheral involvement). Patients with each phenotype were divided into two groups depending on the presence or history of psoriasis. Pair-wise comparisons among the four groups (axial/peripheral phenotype with/without psoriasis) were conducted through univariate logistic regressions and generalized linear mixed models using disease duration and sex as fixed effects and country as random effect. Results: A total of 3291 patients were included in this analysis. The peripheral involvement with psoriasis phenotype showed the highest prevalence of hypertension (44.9%), dyslipidaemia (34%) and diabetes (8.8%), while the axial involvement without psoriasis phenotype exhibited the lowest prevalence of dyslipidaemia (14.2%), diabetes (4.1%) and stroke (0.9%). Among patients with psoriasis, the axial phenotype showed a significantly lower prevalence of hypertension (OR: 0.51, 95% CI: 0.35–0.75) and lower prevalence of Framingham score ⩾15 (OR: 0.57, 95% CI: 0.38–0.85) than patients with peripheral involvement after adjusting for disease duration, sex and country. Among patients with the axial phenotype, patients with psoriasis showed a higher prevalence of hypertension (OR 1.76, 1.40–2.20), dyslipidaemia (OR: 1.99, 95% CI: 1.56–2.53), diabetes (OR: 2.05, 95% CI: 1.39–3.02) and Framingham score ⩾15 (OR: 2.00, 95% CI: 1.57–2.55) than non-psoriatic patients. No differences were found across groups concerning bone metabolism disorders. Conclusion: Both the peripheral phenotype and psoriasis are independently associated with an increased prevalence of cardiovascular risk factors. No differences were found for bone metabolism disorders.

18 August 2023 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
MLMaría Ángeles Puche Larrubia
María Ángeles Puche Larrubia
Clementina López-MedinaClementina López-Medina
Clementina López-Medina
NZNelly Raymond Ziadé
Nelly Raymond Ziadé

5 July 2025 in RMD Open
Verified
Journal Article
Open access
PDF file
LCLaura Cuesta-López
Laura Cuesta-López
IRIván Arias-De la Rosa
Iván Arias-De la Rosa
JMJesús Eduardo Martín-Salazar
Jesús Eduardo Martín-Salazar
ABAntonio Manuel Barranco
Antonio Manuel Barranco
LLLourdes Ladehesa-Pineda
Lourdes Ladehesa-Pineda
NBNuria Barbarroja
Nuria Barbarroja
Objectives: To investigate the impact of sustained C reactive protein (CRP) elevation on cardiovascular (CV) risk factors, particularly endothelial dysfunction and atherosclerosis, in axial spondyloarthritis (axSpA) patients and to explore the underlying molecular mechanisms. Methods: 245 axSpA patients were enrolled. Carotid intima-media thickness (CIMT) and microvascular endothelial function (post-ischaemic reactive hyperaemia) were measured. Retrospective CRP measurements from the past 5 years classified patients as having sustained high CRP if >50% of readings were elevated. Serum levels of 184 inflammation and CV disease-related proteins were analysed using a proximity extension assay, and in vitro studies were conducted in human umbilical vein endothelial cells. Results: 40% of axSpA patients had sustained CRP elevation, showing increased metabolic comorbidities, higher prevalence of atherosclerotic plaques and worse microvascular endothelial function compared with those with intermittent CRP elevations. Proteomic analysis identified 10 altered proteins, with interleukin 6 (IL-6) and CUB domain-containing protein 1 (CDCP-1) linked to endothelial dysfunction, higher CIMT and metabolic disturbances. Paraoxonase 3 (PON-3), the only downregulated protein, showed anti-inflammatory, antioxidant and antiatherogenic properties, restoring endothelial function in vitro. CDCP-1 was associated with atherosclerotic plaques and promoted endothelial adhesion, oxidative stress and inflammation in vitro. Anti-TNF-α therapy reduced inflammatory markers, complement components and the atherogenic index, while increasing high density lipoprotein, apolipoprotein A and PON-3 levels and decreasing IL-6 and CDCP-1 levels. Conclusions: Sustained CRP elevation in axSpA is strongly linked to increased CV risk, endothelial dysfunction and atherosclerosis. IL-6, CDCP-1 and PON-3 emerge as key mediators connecting inflammation to CV risk. Anti-tumour necrosis factor-α therapy improved the metabolic and inflammatory profile and modulated IL-6, CDCP-1 and PON-3 levels, supporting its role in managing CV risks in axSpA.